



## April 2005 BIOTECH SEMINAR

*presented and sponsored by:*  
**THE NORTH AMERICA TAIWANESE ENGINEERS' ASSOCIATION'S**  
**~SIG BIOTECH~**

### **PRESENTATIONS:**

**“Clinical Development of Follow On Products”  
and “Clinical Trials in Central and Eastern Europe” (CEE)”**

**DATE:** Monday, April 11, 2005

**TIME:** 6:30 PM

**LOCATION:** Palo Alto Room, TechMart  
5F, 5201 Great America Pkwy, Santa Clara, CA

**REGISTRATION:** FREE seminar with light refreshment  
RSVP: [ysyang@stanford.edu](mailto:ysyang@stanford.edu) or [slcheng1@yahoo.com](mailto:slcheng1@yahoo.com)

#### **Speaker's BIO:**

**Peter Hans Kalinka, Ph.D., CEO Accelsiors Group International  
CRO, Consultants and Biopharmaceutical Services**

Is co-founder and partner of the Accelsiors Group International and consultant for Biotech Drug Development. He has more than 16 years of experience in the development of therapeutically active proteins. Working for Novartis, he was responsible for the development and filing of the first “generic” Biopharmaceutical in history. In his last position as Head of Clinical Operations of a venture funded Biotech company, he was in charge for the development of 9 Biopharmaceutical compounds, having more than 1000 patients involved in a number of Phase II and III clinical studies at one time. Dr. Kalinka started his career at Biochemie, Austria, a subsidiary of Sandoz. He then held positions such as Senior New Product Manager, Head of Scientific Affairs, Head of Biologics Division and Head of Clinical Operations with companies such as Sandoz, Ares Serono, Novartis and BioPartners. Dr. Kalinka is CEO of a global CRO and Consultancy organisation with a strong presence in the US and Europe.

#### **About the Accelsiors Group International**

Accelsiors Group International headquartered in Europe, is composed of an International CRO, Drug Development Consulting and a Biopharma Development Group. With offices in Germany, Hungary, United States and a partnerships in China, India and Latin America, Accelsiors conducts cost effective, time efficient large multi-centric international trials. Accelsiors' comprehensive project experience developed for Multinational and US companies, provides reliable data and regulatory support for the filing of products with EMEA and FDA, while counseling clients through all project phases, from planning to implementation, from cloning to filing.

Accelsiors intimate involvement with Biologics (Peptides, EPO, Ifn-beta, Ifn-alpha, hGH, SR-Forms) and small molecules (GnRH) contributes proven experience to complicated drug development programs.